FindTrial
Sign In

MLN8237

DRUG6 trials

Sponsors

Abramson Cancer Center at Penn Medicine, New Approaches to Neuroblastoma Therapy Consortium, Washington University School of Medicine, Weill Medical College of Cornell University, Children's Oncology Group

Conditions

AdenocarcinomaHead and Neck CancerNeuroblastomaNeuroendocrine Prostate CancerPancreatic NeoplasmsProstate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine MarkersProstate CancerSmall Cell Prostate Cancer

Phase 1

MLN8237 in Head and Neck Cancer
CompletedNCT01540682
Abramson Cancer Center at Penn MedicineHead and Neck Cancer
Start: 2012-02-29Target: 9Updated: 2018-08-29
Study of MLN8237 in Combination With Irinotecan and Temozolomide
CompletedNCT01601535
New Approaches to Neuroblastoma Therapy ConsortiumNeuroblastoma
Start: 2012-05-31End: 2018-07-25Updated: 2019-07-31
Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
CompletedNCT01677559
Washington University School of MedicineAdenocarcinoma, Pancreatic Neoplasms
Start: 2013-05-07End: 2017-08-11Updated: 2018-01-11
MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors
CompletedNCT02444884
Children's Oncology GroupNeuroblastoma, Unspecified Childhood Solid Tumor, Excluding CNS
Start: 2008-09-30End: 2011-12-31Updated: 2016-02-09

Phase 2

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
CompletedNCT01799278
Weill Medical College of Cornell UniversityNeuroendocrine Prostate Cancer, Prostate Adenocarcinoma Plus > 50% Immunohistochemical Staining for Neuroendocrine Markers, Small Cell Prostate Cancer
Start: 2013-02-28End: 2017-08-31Updated: 2018-01-23

Unknown Phase

MLN8237 for a Subject With Adenocarcinoma of the Prostate
NCT03005262
The University of Texas Health Science Center at San AntonioProstate Cancer
Updated: 2018-04-04

Related Papers

Population Pharmacokinetics and Exposure‐Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies
The Journal of Clinical Pharmacology2021-08-268 citations
Phase 1 study combining alisertib with nab-paclitaxel in patients with advanced solid malignancies.
2021-07-1011 citations
Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.
Journal of Clinical Oncology2017-05-20
Phase II study of alisertib, irinotecan, and temozolomide in children with relapsed and refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy (NANT) consortium.
Journal of Clinical Oncology2016-05-202 citations
The Treatment Challenges of Neuroendocrine Prostate Cancer
Oncology Times2015-02-122 citations
Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.
Journal of Clinical Oncology2014-05-20
Circulating tumor cell (CTC) enumeration in patients with metastatic neuroendocrine prostate cancer (NEPC) and castration-resistant prostate cancer (CRPC).
Journal of Clinical Oncology2014-02-015 citations